Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of CD388 (efitazanamivir alfa/MK-1406) for influenza prevention in high-risk adults and adolescents
2026-527531-33-00Phase 3Authorised
- Sponsor
- Cidara Therapeutics
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in influenza comparing efitazanamivir alfa with placebo comparator (2 arms). Planned start Oct 2026; status: authorised.
02
Drugs
efitazanamivir alfa
03
Conditions
influenza
Beyond the preview
Go deeper on 2026-527531-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527531-33-00.